Skip to main content

Advertisement

Table 3 Phone-based survey of treatment outcomes of EIB and TB-AOI cases - Alberta, 2004–14

From: Program-wide review and follow-up of erythema Induratum of Bazin and tuberculosis-associated ocular inflammation management in a TB low-incidence setting: need for improved treatment candidate selection, therapy standardization, and care collaboration

  EIB (n = 21) TB-AOI (n = 20)
Phone Follow-up – no. (%) n = 13 (62) n = 11 (55)
Time post ATT – month (year)
 Median 61 (5.1) 49 (4.1)
 IQR 34 (2.8) 48 (4)
Responses
 “Do you still have (EIB/TB-AOI)?”
  Resolved – no. (%) 8 (62) 2 (18)
  Better 2 (15) 3 (28)
  Worse 0 (0) 0 (0)
  No change 3 (23) 6 (54)
 “How did your condition respond to the ATT?”
  Min (< 25% improvement) 1 (8) 8 (73)
  Mod (~ 50%) 1 (8) 1 (9)
  Significantly (~ 75%) 2 (15) 0 (0)
  Complete (100%) 7 (54) 2 (18)
 “How did you tolerate the ATT?”
  Poorly 5 (38) 3 (28)
  Well 5 (38) 2 (18)
  No issue 3 (24) 6 (54)
  1. EI – erythema induratum, TB-AOI – tuberculosis-associated ocular inflammation, ATT – anti-tubercular therapy